Safety and efficacy of fecal microbiota transplantation in intractable bowel diseases

Safety and efficacy of fecal microbiota transplantation in intractable bowel diseases - Fecal microbiota transplantation in bowel diseases

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012814

Enrollment

Registered

2014-01-10

Start date

2014-01-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis, Intestinal Behcet, Clostridium difficile infection

Interventions

Administration of feces obtained from healthy donors to patients.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Ulcerative colitis patients with moderate to severe activity despite treatment with corcicosteroids, anti-TNFa Ab, tacrolimus or immunomodulators. 2. Patients with intestinal Behcet's disease who have ulcers in the intestine despite treatment with corcicosteroids or anti-TNFa Ab. 3. Patients with C. difficile infection who have gastrointestinal symptoms despite administration of vancomycin or metronidazole. 4. Donors should be patient's spouse or first- or second-degree relatives.

Exclusion criteria

Exclusion criteria: 1. Donors who show abnormal findings to the screening tests including blood and feces.

Design outcomes

Primary

Measure	Time frame
Safety Efficacy	—

Countries

Japan

Contacts

Public ContactKosaku Nanki

Department of Internal Medicine, Keio University School of Medicine Division of Gastroenterology and Hepatology

kosakun214@hotmail.com03-3353-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026